



**PACIFIC RESEARCH NETWORK**

3003 Fourth Avenue, San Diego, CA 92103 \* (619) 294-4302 Ph. (619) 294-4867 Fax

**MARYANN DEAN, M.D.**

**EDUCATION**

2001 – 2002 Psychiatry: University of California, San Diego, California  
1998 – 2001 Psychiatry: State University of New York, Buffalo, New York  
1994 – 1998 Medical: State University of New York, Buffalo, New York  
1991 – 1993 Pre-Medical: State University of New York, Buffalo, New York  
1979 – 1981 MFA: West Virginia University, Morgantown, West Virginia  
1977 – 1979 BA: West Liberty State College, West Liberty, West Virginia  
1970 – 1973 Preparatory: Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

**MEDICAL EXPERIENCE**

2003 – Present Staff Physician, Pacific Research Network, San Diego, California  
2003 – Present Psychiatrist, San Diego County Psychiatric Hospital, San Diego, California  
2003 – Present Psychiatrist, Survivors of Torture International, San Diego, California  
2002 – 2003 Clinical Instructor, Psychiatrist, UCSD Outpatient Services, San Diego, California  
2002 – 2003 Psychiatrist, Neighborhood Services and Interfaith Community Services, Escondido, California  
1979 Psychiatric Assistant, Northern Panhandle Mental Health Center, Wheeling, West Virginia  
1976 Laboratory Assistant, Instituto Mexicano del Seguro Social, Mexico City, Mexico

**RESEARCH AND VOLUNTEER ACTIVITIES**

1994 Research Assistant, State University of New York, Buffalo, New York  
1993 Nursing Assistant, Roberto Clemente Clinic, Buffalo, New York  
1992 Assistant, Roswell Park Cancer Institute, Buffalo, New York  
1992 Caretaker, Benedict House, Buffalo, New York

**CERTIFICATION AND LICENSURE**

2003 Board Certification in Psychiatry

**LICENSURE:** State of California  
License Number: A70889  
Expiration Date: February 29, 2008

## **HONORS AND AWARDS**

PRITE Award  
The Gilbert M. Beck Memorial Prize  
Association of Pathology Chairs Award  
American Medical Women's Association

## **PROFESSIONAL ORGANIZATIONS**

Member of The National Alpha Omega Alpha Honor Medical Society  
Member of the Association of Pathology Chairs Honor Society  
Member of the American Psychiatry Association

## **CLINICAL RESEARCH EXPERIENCE**

1. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome (203233)
2. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy (203231)
3. A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment (202493)
4. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of XXXX in Patients with Mild-To-Moderate Dementia of the Alzheimer's Type (202793)
5. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease (202530)
6. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Fixed-Dose, Polysomnographic Study of XXXX in Patients with Primary Insomnia (202700)
7. A Multi-Center, Randomized, Open-Label Study Evaluating the Effects of XXXX, 80 mg b.i.d., vs. XXXX, 5 or 10 mg, on Adrenal Function in Patients with Mild Alzheimer's Disease (202538)
8. An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of XXXX in the Treatment of Mild Cognitive Impairment (5075)
9. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease (2920)
10. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of XXXX in Subject with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease (2919)
11. A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the Safety and Efficacy of XXXX, 80 mg bid, and 20 and 80 mg QD in the Treatment of Mild to Moderate Alzheimer's Disease (4807)

12. A Long Term Safety and Efficacy of Open-Label XXXX, 80 mg b.i.d. in the Treatment of Probable Alzheimer's Disease: A 18-Month Follow-Up After Completion of Study XXXX (202859)
13. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties (4315)
14. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXXX in Adult Patients with Primary Insomnia (3934)
15. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of Two Dose Levels of XXXX in Elderly Patients With Primary Insomnia (3931)
16. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of XXXX 25 mg in Slowing the Progression of Alzheimer's Disease (202531)
17. A Randomized, Double-Blind, Placebo-Controlled, 4-Period-Cross-Over Pilot Study of the Safety and Efficacy of Multiple Doses of XXXX in Subjects with Alzheimer's Disease (202856)
18. An Evaluation of the Long-Term Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type (202891)
19. A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of XXXX, at Dosages up to 16 mg/day in Adults with Generalized Anxiety Disorder (202976)
20. Pharmacogenomics Blood Sampling Protocol to Obtain DNA in a Reference Population of Patients Diagnosed with Restless Legs Syndrome (5152)
21. A Long-Term, Open-Label, Flexible-Dose Study of the Efficacy and Safety of XXXX in Patients with Idiopathic Restless Legs Syndrome (4382)
22. An 8-Week, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of XXXX, at Dosages up to 16 mg/day, in the Treatment of Generalized Anxiety Disorder in Adults (202359)
23. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX Monotherapy in Patients with Moderate to Severe Dementia of the Alzheimer's Type (4988)
24. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type (4887)
25. A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type (3811x1)
26. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type. IND#: 33,392 (4441)

27. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXXX in Adult Patients with Primary Insomnia (3934)
28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00012)
29. A Study to Define the Non-Restorative Sleep Population. (00010)
30. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease. (00026)
31. A Double-Blind, Placebo-Controlled, Parallel Group Study, with an Open-Label Extension Phase, to Assess the Efficacy, Tolerability and Safety of Oral XXXX in the Prevention of Menstrually-Related Migraine (MRM) Headaches in a "difficult to treat" Population. (00018)
32. A 6-Month Safety Follow-Up Study of Select Patients Previously Enrolled and Randomized to XXXX in Studies XXXX, XXXX or XXXX. (00028)
33. Evaluation of the Long-Term Efficacy and Safety of XXXX 12.5-mg Compared to Placebo, When Both are Administered Over a Long-Term Period "as needed", in Patients with Chronic Primary Insomnia. (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study). (00007)
34. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (203812PRN)
35. A Phase III Study of the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203077PRN)
36. A Double-Blind, Phase II, Safety and Efficacy Evaluation of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203096PRN)
37. A 12-Month, Open-Label, Flexible-Dosage (100-250 mg/day) Extension Study of the Safety and Efficacy of XXXX in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. (203903)
38. A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00025)
39. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once Daily XXXX in Patients with Restless Legs Syndrome. (00036)
40. Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (00023)

41. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Primary Insomnia Patients with Sleep Maintenance Difficulties. (00047)
42. A Double Blind, Placebo Controlled Study of XXXX for the Treatment of Mild-To-Moderate Alzheimer's Disease. (00065)
43. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (00056)
44. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of XXXX (2.5, 10 and 30 mg) on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia. (00088)
45. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly. (00058)
46. A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate Effects of the XXXX in Patients with Insomnia. (00077)
47. A Randomized, Double-Blind Comparison of 5 mg of XXXX, 15 mg of XXXX, and Placebo in the Treatment of Patients with Primary Insomnia. (00076)
48. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prophylaxis. (00082)
49. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XXXX in Patients with Generalized Anxiety Disorder. (00054)
50. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00046)
51. An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00093)
52. A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Patients with Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered XXXX. (00063)
53. The Efficacy of XXXX 3 mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder (GAD). (00057)
54. A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXXX XR (Extended Release) in Patients with Restless Legs Syndrome. (00059)
55. A 52-Week, Open-Label Study to Assess the Long-Term Safety of XXXX Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). (00075)

56. An Open-Label Extension of the Phase III Study XXXX with XXXX in Patients with Alzheimer's Disease. (00107)
57. A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of XXXX (XXX) in Subjects with Mild Cognitive Impairment. (00105)